Weili Zhibo: Vailixin has been granted IND approval by the National Medical Products Administration for the treatment of metastatic colorectal cancer.

On August 3, Vili Zhi Bo announced on the Hong Kong Stock Exchange that the Drug Evaluation Center of the National Medical Products Administration has approved its self-developed candidate drug Vili Xin for a clinical trial application aimed at treating metastatic colorectal cancer. The approved clinical trial is an open-label, multi-center Phase Ib/II study designed to evaluate the safety and efficacy of Vili Xin in combination therapy for mCRC.